Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atrasentan in Proteinuric Glomerular Diseases
NCT04573920Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of atrasentan in IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), Alport syndrome and 1 more (2 arms), sponsored by Novartis. Primary endpoints: Change in proteinuria at 30 weeks and Change in albuminuria at 12 weeks. Started Mar 2021; status: active, not recruiting.
02
Drugs
atrasentan
03
Conditions
IgA nephropathy (IgAN)focal segmental glomerulosclerosis (FSGS)Alport syndromediabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT04573920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04573920.